Therefore, the identification of KIF4A as a regulator of PAI-1 provides valuable insight into the molecular mechanisms underlying cancer progression and emphasizes the potential of both KIF4A and PAI-1 as novel therapeutic targets in lung cancer and glioma. Here, KIF4A is linked to central nervous system cancer.